Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Sanquin neemt deel aan internationale alliantie ter ontwikkeling COVID-19-geneesmiddel
mei 2020 | Virale infecties